Secondary Hormone Therapy for Castration-Resistant Prostate Cancer

Secondary Hormone Therapy for Castration-Resistant Prostate Cancer

The majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant prostate cancer (CRPC). CRPC is defined by prostate-specific antigen (PSA) or radiographic progression in the

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.